Hangzhou and New Jersey-based cancer biotech Adlai Nortye Ltd. – formerly Hangzhou Nuotai Pharmaceutical Co. Ltd. – announced plans to list on Nasdaq with its U.S. IPO filed on July 27.

European biotech investor Medicxi announced the closure of its fourth fund at $400 million, a sum it said is “deliberately sized” for its asset-focused investment model.

The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions which continue to have significant unmet needs – has taken a small step forward as one company, Violet Therapeutics Inc., plans to put $10.6 million in seed funding toward building out a pipeline based on technologies that elucidate the way cells interact amongst one another.

With Aeon Biopharma Inc. listing on the New York Stock Exchange (NYSE) on July 24, South Korea’s Daewoong Pharmaceutical Co. Ltd. is seeking new territory for its beleaguered botulinum toxin (BTX) product, Nabota (Jeuveau or ABP-450 in the U.S). Aeon’s move is expected help expand Nabota beyond aesthetic treatment to include medical conditions such as episodic migraines, cervical dystonia and post-traumatic stress disorder (PTSD).

Pursuing tumor-infiltrating lymphocytes (TILs), Turnstone Biologics Inc. raised about $80 million in an IPO, offering 6.7 million shares at $12 each. The firm is “pioneering a differentiated approach to TILs,” with next-generation products designed by choosing the most potent and tumor-reactive T cells, dubbed Selected TILs, according to SEC paperwork.